Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals is a clinical-stage company based in Norwood, Massachusetts, focused on developing therapies for people with cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets Nectin-4 on cancer cells and delivers a cytotoxic payload. Corbus is conducting a Phase 1/2 study of CRB-701 in the U.S. and Europe for patients with advanced solid tumors associated with Nectin-4 expression. The company is also developing CRB-913, an oral cannabinoid type-1 receptor inverse agonist for obesity. Corbus holds licenses to develop and commercialize CRB-701 in specified territories and to develop and market certain cannabinoid compounds worldwide. It relies on contract manufacturers and licensing partners to supply drugs for studies and commercial activities.
No enriched coverage for $CRBP in the last 7 days.
Cormorant Asset Management, LP sold 425,000 indirectly-held shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $4.10 ($1.74M total) on 2026-10-29. Filed jointly with Cormorant Global Healthcare Master Fund, LP and Chen Bihua.
Corbus Pharmaceuticals updated its corporate presentation, reporting progress in CRB-701 for OPSCC and positive Phase 1b results for CRB-913 in obesity. The company has $118M in cash and expects interim ORR readout for CRB-701 in Q1 2027. CRB-913 showed ~5% placebo-adjusted weight loss at 12 weeks, with Phase 2 trials planned for 1H 2027.
Corbus Pharmaceuticals (CRBP) fell 14.36% to $6.92 on Tuesday, extending its losing streak to eight days. The NASDAQ and Dow Jones also declined, down 0.78% and 0.63% respectively.
Recent CRBP coverage spans technology, insider activity and corporate actions.
In the last 30 days, CRBP insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.7M). The most active reporter was Cormorant Asset Management, LP with 1 filing.
Insider sale may signal lack of confidence, prompting short-term price pressure.
Positive early‑stage data and clear regulatory timeline may lift investor sentiment.
Significant intraday decline suggests short-term bearish pressure.
Positive trial data may boost CRBP stock as investors anticipate Phase 2 and potential market entry.
Positive trial data may boost CRBP share price and attract investor interest in a new obesity drug class.
AlphAI scores every news story that mentions CRBP with an AI model for sentiment and relevance, and aggregates insider trades from Corbus Pharmaceuticals Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cormorant Asset Management, LP sold 425,000 indirectly-held shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $4.10 ($1.74M total) on 2026-10-29. Filed jointly with Cormorant Global Healthcare Master Fund, LP and Chen Bihua.
1 min readCorbus Pharmaceuticals updated its corporate presentation, reporting progress in CRB-701 for OPSCC and positive Phase 1b results for CRB-913 in obesity. The company has $118M in cash and expects interim ORR readout for CRB-701 in Q1 2027. CRB-913 showed ~5% placebo-adjusted weight loss at 12 weeks, with Phase 2 trials planned for 1H 2027.
1 min readCorbus Pharmaceuticals (CRBP) fell 14.36% to $6.92 on Tuesday, extending its losing streak to eight days. The NASDAQ and Dow Jones also declined, down 0.78% and 0.63% respectively.
1 min readCorbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.
2 min readCorbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development
2 min readCorbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.
2 min readCorbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau obs
2 min readSaxena Nishant C (Chief Business Officer) purchased 2,600 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $9.63 on 2026-08-11.
1 min readCorbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last
5 min readCorbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 crbp-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “ Agreement ”), dated as of August 03, 2026 (the “ Effective Date ”), is entered into by and between Corbus Pharmaceuticals Holdings, Inc. (the “ Company ”) and Leonardo Vi
2 min read
